Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 925 of 3499 entries
View as:

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01238133 Org: User:
Start: 12/31/10 End: 08/31/15 Due: 08/31/16

A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01445106 Org: User:
Start: 12/11/06 End: 05/09/11 Due: 05/09/12

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00003595 Org: User:
Start: 01/31/99 End: - Due: -

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00085111 Org: User:
Start: 12/31/03 End: - Due: -

Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00001440 Org: User:
Start: 07/31/95 End: 01/31/02 Due: 01/31/03

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00096109 Org: User:
Start: 09/30/05 End: 05/31/12 Due: 05/31/13

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02129075 Org: User:
Start: 04/09/14 End: 05/18/18 Due: 05/18/19

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Phase: N/A Priority: Normal
NCT ID: NCT01313429 Org: User:
Start: 03/04/11 End: 02/26/20 Due: 02/26/21

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT02798536 Org: User:
Start: 07/27/16 End: 04/21/22 Due: 04/21/23

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02830724 Org: User:
Start: 04/06/17 End: 01/01/28 Due: 01/01/29

Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

Phase: N/A Priority: Normal
NCT ID: NCT02154022 Org: User:
Start: 07/31/14 End: 05/01/30 Due: 05/01/31

Optimizing PTCy Dose and Timing

Phase: N/A Priority: Normal
NCT ID: NCT03983850 Org: User:
Start: 07/09/19 End: 08/01/26 Due: 08/01/27

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04417660 Org: User:
Start: 12/26/20 End: 12/31/26 Due: 12/31/27

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01654965 Org: User:
Start: 07/24/12 End: 03/29/18 Due: 03/29/19

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

Phase: N/A Priority: Normal
NCT ID: NCT00006425 Org: User:
Start: 12/19/00 End: 10/03/08 Due: 10/03/09

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Phase: N/A Priority: Normal
NCT ID: NCT02579967 Org: User:
Start: 11/19/15 End: 12/21/28 Due: 12/21/29

Anti-Tac for Treatment of Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00001941 Org: User:
Start: 12/31/99 End: 02/28/11 Due: 02/28/12

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00253578 Org: User:
Start: 03/31/06 End: - Due: -

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00462826 Org: User:
Start: 11/30/07 End: 01/31/13 Due: 01/31/14

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01175343 Org: User:
Start: 07/31/10 End: 08/31/15 Due: 08/31/16

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Phase: N/A Priority: Normal
NCT ID: NCT01143402 Org: User:
Start: 06/30/10 End: 05/31/16 Due: 05/31/17

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00053365 Org: User:
Start: 06/30/03 End: 07/31/10 Due: 07/31/11

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01274338 Org: User:
Start: 05/25/11 End: 03/19/26 Due: 03/19/27

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01167712 Org: User:
Start: 09/27/10 End: 06/18/25 Due: 06/18/26

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00114101 Org: User:
Start: 12/15/04 End: 02/22/26 Due: 02/22/27